Bristol-Myers Squibb Co (BMY) : New England Research Management scooped up 13,717 additional shares in Bristol-Myers Squibb Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 5, 2016. The investment management firm now holds a total of 20,867 shares of Bristol-Myers Squibb Co which is valued at $1,143,303.Bristol-Myers Squibb Co makes up approximately 0.96% of New England Research Management’s portfolio.
Other Hedge Funds, Including , Eqis Capital Management boosted its stake in BMY in the latest quarter, The investment management firm added 754 additional shares and now holds a total of 16,006 shares of Bristol-Myers Squibb Co which is valued at $876,969. Bristol-Myers Squibb Co makes up approx 0.06% of Eqis Capital Management’s portfolio.Lynch Associatesin boosted its stake in BMY in the latest quarter, The investment management firm added 257 additional shares and now holds a total of 17,336 shares of Bristol-Myers Squibb Co which is valued at $949,839. Bristol-Myers Squibb Co makes up approx 0.42% of Lynch Associatesin’s portfolio.Washington Trust Bank boosted its stake in BMY in the latest quarter, The investment management firm added 158 additional shares and now holds a total of 11,111 shares of Bristol-Myers Squibb Co which is valued at $608,772. Bristol-Myers Squibb Co makes up approx 0.15% of Washington Trust Bank’s portfolio.Harbour Capital Advisors reduced its stake in BMY by selling 310 shares or 1.84% in the most recent quarter. The Hedge Fund company now holds 16,513 shares of BMY which is valued at $904,747. Bristol-Myers Squibb Co makes up approx 0.49% of Harbour Capital Advisors’s portfolio.
Bristol-Myers Squibb Co opened for trading at $54.9 and hit $55.82 on the upside on Tuesday, eventually ending the session at $55.21, with a gain of 1.01% or 0.55 points. The heightened volatility saw the trading volume jump to 1,40,42,673 shares. Company has a market cap of $92,248 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Shares were Reiterated by Barclays on Sep 9, 2016 to “Equal Weight” and Lowered the Price Target to $ 65 from a previous price target of $75 .Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.